Disease-Modifying Therapies in Transthyretin Amyloid Cardiomyopathy: What Have We Achieved?
Publication
, Journal Article
Khouri, MG; Fajardo, J; Lewis, M; Gunn, AH
Published in: J Card Fail
February 14, 2026
Duke Scholars
Published In
J Card Fail
DOI
EISSN
1532-8414
Publication Date
February 14, 2026
Location
United States
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Khouri, M. G., Fajardo, J., Lewis, M., & Gunn, A. H. (2026). Disease-Modifying Therapies in Transthyretin Amyloid Cardiomyopathy: What Have We Achieved? J Card Fail. https://doi.org/10.1016/j.cardfail.2026.01.011
Khouri, Michel G., Johana Fajardo, Morgan Lewis, and Alexander H. Gunn. “Disease-Modifying Therapies in Transthyretin Amyloid Cardiomyopathy: What Have We Achieved?” J Card Fail, February 14, 2026. https://doi.org/10.1016/j.cardfail.2026.01.011.
Khouri MG, Fajardo J, Lewis M, Gunn AH. Disease-Modifying Therapies in Transthyretin Amyloid Cardiomyopathy: What Have We Achieved? J Card Fail. 2026 Feb 14;
Khouri, Michel G., et al. “Disease-Modifying Therapies in Transthyretin Amyloid Cardiomyopathy: What Have We Achieved?” J Card Fail, Feb. 2026. Pubmed, doi:10.1016/j.cardfail.2026.01.011.
Khouri MG, Fajardo J, Lewis M, Gunn AH. Disease-Modifying Therapies in Transthyretin Amyloid Cardiomyopathy: What Have We Achieved? J Card Fail. 2026 Feb 14;
Published In
J Card Fail
DOI
EISSN
1532-8414
Publication Date
February 14, 2026
Location
United States
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology